Showing 21,141 - 21,160 results of 34,844 for search '(( 50 ((a decrease) OR (nn decrease)) ) OR ( e ((point decrease) OR (fold decrease)) ))', query time: 1.01s Refine Results
  1. 21141
  2. 21142

    SmInAct Is Essential for Egg Development by Tori C Freitas (69299)

    Published 2007
    “…Data are presented as mean percent developed (+/− s.d.) from four separate experiments.</p><p>(E) SmInAct protein levels are decreased by approximately 10-fold following treatment with <i>SmInAct</i> dsRNA. …”
  3. 21143

    Gene expression profiles & Gene set Enrichment analysis. by Jeongmin Lee (482745)

    Published 2025
    “…Genes were filtered using a threshold of p-value ≤ 0.05 and (|Fold Change|) ≥ 2 Both rows (genes) and columns (samples) were subjected to hierarchical clustering. …”
  4. 21144

    Expression levels of p115RhoGEF affect cell migration. by Swapnil S. Kher (513448)

    Published 2014
    “…Individual cell positions in sequential images were determined using the cell tracking tool in Slidebook software and x-y co-ordinates with starting points adjusted to (0,0) were plotted. Migration of 5 cells was measured in each experiment and data was pooled from three individual experiments. p115-OE MDA-MB-231 cells displayed decreased migration as compared to control cells that expressed GFP alone. …”
  5. 21145
  6. 21146
  7. 21147
  8. 21148

    BPLF1 selectively inhibits the detection of TOP2-induced DNA damage. by Jinlin Li (2267896)

    Published 2021
    “…The expression of catalytically active BPLF1 was associated with a significant decrease of Etoposide induced nuclear γH2AX fluorescence and decreased formation of 53BP1 foci. …”
  9. 21149
  10. 21150
  11. 21151
  12. 21152
  13. 21153
  14. 21154

    Astilbin exerts anti-hypersensitivity by regulating metabolic demand and neuronal activity in rodent model of neuropathic pain by Qiru Wang (12260453)

    Published 2024
    “…</p> <p>In experiments conducted on neuropathic rats, both systemic and intrathecal administration of astilbin, an essential constituent, exhibited a noteworthy and dose-dependently decrease in chronic and acute pain behaviours. …”
  15. 21155

    Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts by Li Liu (75607)

    Published 2012
    “…The current study evaluated the vascular-disrupting activity of BPR0L075 in human breast cancer mammary fat pad xenografts using dynamic bioluminescence imaging. A single dose of BPR0L075 (50 mg/kg, intraperitoneally (i.p.)) induced rapid, temporary tumor vascular shutdown (at 2, 4, and 6 hours); evidenced by rapid and reproducible decrease of light emission from luciferase-expressing orthotopic MCF7 and MDA-MB-231 breast tumors after administration of luciferin substrate. …”
  16. 21156
  17. 21157
  18. 21158
  19. 21159
  20. 21160